A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer

Mostrar otras versiones (1)

To evaluate the tumour response to lomeguatrib and temozolomide (TMZ) administered for 5 consecutive days every 4 weeks in patients with metastatic colorectal carcinoma. Patients with stage IV metastatic colorectal carcinoma received lomeguatrib (40 mg) and TMZ (50–200 mg m(−2)) orally for 5 consecu...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, O A, Ranson, M, Michael, M, Olver, I, Levitt, N C, Mortimer, P, Watson, A J, Margison, G P, Midgley, R, Middleton, M R
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2391129/
https://www.ncbi.nlm.nih.gov/pubmed/18475294
http://dx.doi.org/10.1038/sj.bjc.6604366

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2391129/
https://www.ncbi.nlm.nih.gov/pubmed/18475294
http://dx.doi.org/10.1038/sj.bjc.6604366

Ejemplares similares